Silence Therapeutics plc (SLN) Short-Term Debt to Equity

The price history of Silence Therapeutics (SLN) shares on the GURU.Markets platform demonstrates metric indicators at the level of 0.00. Silence Therapeutics is a pioneer in the targeted silencing of pathological genes via siRNA, investing colossal resources into the fight against orphan diseases. The business relies on GalNAc technologies for the therapy of cardiac issues by suppressing genes in the liver. Successful trials of drugs against cardiovascular threats are creating a positive backdrop.

Silence Therapeutics operates in the high-risk RNA interference sector, relying entirely on partner payments in the absence of its own operating revenues. The short-term debt-to-equity ratio compares liabilities with maturities exceeding one year against net assets to assess credit sustainability. The market interprets this proportion as a liquidity indicator or a signal for expansion. The trend in the short-term debt-to-equity ratio reflects the balance between external financing and the company's capital base.